Alzheimer’s Disease and Dementia

Alzheimer’s and Parkinson’s Diseases are the maximum not unusual place neurodegenerative diseases. An expected 24 million humans around the world be afflicted by Dementia and Alzheimer disorder accommodates 60% of this number. Alzheimer disorder is characterized pathologically through cerebral atrophy and clinically through mastering impairment. According to the Alzheimer’s Association, 13% of humans over 65 are afflicted by Alzheimer disorder in advanced countries. It is the 5th main purpose of demise in sufferers at this age.

The purpose of Alzheimer disorder is unknown and contemporary remedies are symptomatic. Current remedies for cognitive impairment in Alzheimer disorder are primarily based totally on neurotransmitter or enzyme replacement. These offer extensive spectrum of symptomatic blessings and consist of acetylcholinesterase inhibitors, antioxidants, amyloid-centred pills, and nerve boom factors. It appears that not one of the to be had treatment plans are capable of remedy Alzheimer disorder or to reduce its progression.

Nanotechnology can also additionally offer a possible answer to conquer many barriers for the remedy of Alzheimer disorder through affording centred drug transport and improving the bioavailability and efficacy of numerous pills and different bioactive agents.

Related Associations:

Neuropathy Association and Nevus Outreach, Inc, Brain Injury Resource Center and Brain Trauma Foundation, Epilepsy Therapy Project and Exceptional Parent Magazine , Huntington's Disease Society of America Hydrocephalus Association, Multiple Sclerosis Association of America and Multiple Sclerosis Foundation, Multiple System Atrophy Coalition, Acoustic Neuroma Association and ADA Disability and Business Technical Assistance Program; Aicardi Syndrome Foundation and Alliance for Aging Research; ALS Association and ALS Therapy Development Institute; Alternating Hemiplegia of Childhood Foundation and Alzheimer's Drug Discovery Foundation.